Head-To-Head Contrast: Sirona Dental Systems (SIRO) vs. Accelerate Diagnostics (AXDX)

Sirona Dental Systems (NASDAQ: SIRO) and Accelerate Diagnostics (NASDAQ:AXDX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.


This table compares Sirona Dental Systems and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sirona Dental Systems 17.03% 15.23% 11.01%
Accelerate Diagnostics -3,085.36% -60.99% -57.85%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sirona Dental Systems and Accelerate Diagnostics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sirona Dental Systems 0 0 0 0 N/A
Accelerate Diagnostics 0 1 1 0 2.50

Accelerate Diagnostics has a consensus price target of $33.00, suggesting a potential upside of 41.94%. Given Accelerate Diagnostics’ higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Sirona Dental Systems.

Earnings and Valuation

This table compares Sirona Dental Systems and Accelerate Diagnostics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sirona Dental Systems N/A N/A N/A $3.39 32.44
Accelerate Diagnostics $250,000.00 5,152.20 -$66.37 million ($1.20) -19.37

Sirona Dental Systems has higher earnings, but lower revenue than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Sirona Dental Systems, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

47.6% of Accelerate Diagnostics shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Sirona Dental Systems has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.


Accelerate Diagnostics beats Sirona Dental Systems on 6 of the 10 factors compared between the two stocks.

About Sirona Dental Systems

Sirona Dental Systems, Inc. is a manufacturer of dental equipment. The Company is focused on developing, manufacturing and marketing solutions for dentists around the world. It operates through four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers and Instruments. Its Dental CAD/CAM Systems includes several types of restorations, such as inlays, onlays, veneers, crowns, bridges, copings and bridge frameworks made from ceramic metal or composite blocks. Its Imaging Systems segment consists of a range of systems for diagnostic imaging in the dental practice. Its Treatment Centers consist of a range of products from basic dentist chairs to chair-based units with integrated diagnostic hygiene and ergonomic functionalities, as well as specialist centers used in preventative treatment and for training purposes. It offers a range of instruments, including handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Sirona Dental Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sirona Dental Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply